"Designing Growth Strategies is in our DNA"

Mechanical Circulatory Support Devices Market Size, Share & Industry Analysis, By Product Type, By Patient Group, By Application, By End-user, and Regional Forecast, 2026-2034

Last Updated: November 19, 2026 | Format: PDF | Report ID: FBI119771

 

Mechanical Circulatory Support Devices Market Size and Future Outlook

Play Audio Listen to Audio Version

The global mechanical circulatory support devices market size was valued at USD 3.59 billion in 2025. The market is projected to grow from USD 4.01 billion in 2026 to USD 8.58 billion by 2034, exhibiting a CAGR of 10.0% during the forecast period.

Mechanical Circulatory Support (MCS) devices are specialized medical machines that assist or replace the pumping function of a weakened heart to keep blood moving through the body. These devices improve blood flow to vital organs and reduce the workload on the heart. Certain extracorporeal support systems may also provide blood oxygenation when integrated with an oxygenator. Market growth is attributed to the increasing prevalence of cardiovascular diseases, particularly heart failure. 

Abbott, ABIOMED, Getinge, Teleflex Incorporated, and Berlin Heart held the highest market share in 2025, supported by established brand recognition, broad product portfolios, and extensive global distribution networks.

Shift Toward Advanced Pump-Based MCS Technologies to Emerge as a Key Trend

The market is witnessing a shift toward more advanced pump technologies that can provide improved hemodynamic support with improved efficiency and durability. In temporary mechanical circulatory support, catheter-based pumps are gaining adoption as they provide direct ventricular support and higher blood flow compared with traditional IABP systems.

On the other hand, the durable MCS devices are increasingly utilizing magnetically levitated rotary pumps to reduce mechanical contact and wear inside the device. Key products such as the HeartMate 3 have helped in the establishment of this technology in long-term support. Moreover, as healthcare facilities expand their use of these technologies, catheter-based and magnetically levitated pumps are anticipated to gain importance.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Growing Use of Temporary MCS in Cardiogenic Shock and High-Risk PCI Fuels Market Growth

Over the past few years, the use of temporary mechanical circulatory support devices has increased in cardiogenic shock, acute heart failure, and high-risk PCI. Catheter-based heart pumps can be implanted or inserted rapidly in appropriate clinical settings. Moreover, their adoption is growing due to greater physician experience, wider availability of catheterization laboratories equipped to provide mechanical circulatory support, and the use of dedicated shock-treatment protocols. Furthermore, the increasing prevalence of heart failure and related cardiac conditions contributes to the market growth.

  • For instance, according to data published by the Centers for Disease Control and Prevention (CDC) in May 2024, approximately 6.7 million U.S. adults aged 20 years or older were living with heart failure in the U.S.

Market Drivers - Impact & CAGR Contribution (2026–2034)

Rank Market Drivers Expected Impact on Market Growth Estimated Gross Market Growth Contribution (USD Billion)
(2026-2034)
Impact: 2026-2028 Impact: 2029-2031 Impact: 2032-2034
1 Growing use of temporary MCS in cardiogenic shock and high-risk PCI High 1.75 High High High
2 Rising burden of advanced heart failure, cardiogenic shock and donor-heart shortage High 1.45 High High High
3 Expansion of catheter-based temporary MCS in cardiogenic shock and high-risk PCI Medium-High 1.2 High High Medium
4 Durable LVAD technology improvements and broader long-term support eligibility Medium-High 0.95 Medium High High
5 Expansion of advanced cardiac centers and reimbursement/coverage pathways Medium 0.83 Medium Medium Medium
6 Emerging-market commercialization and tertiary cardiac infrastructure growth Low 0.44 Low Low Low
Total Gross Growth Contribution 6.62  

Source: Fortune Business Insights

Download Free sample For In-Depth Market Drivers & Impact Forecasts

MARKET RESTRAINTS

Risk of Device-Related Complications to Limit Market Growth

Although mechanical circulatory support devices provide life-saving support to critically ill patients, their invasive nature carries risks of serious complications such as bleeding, vascular injury, blood clots, stroke, hemolysis, infection, and device malfunction. Such complications increase the need for physician training, careful patient selection, and continuous monitoring, potentially limiting the adoption of these devices.

Safety concerns may also lead to regulatory actions, labeling updates, or product recalls. For instance, in March 2024, the FDA announced a Class I recall involving a correction to the instructions for use of certain Impella left-sided blood pumps following reports of 129 serious injuries and 49 reported deaths, associated with the risk of cardiac perforation. Such safety concerns may increase hospitals' caution when adopting MCS devices. This is anticipated to hinder the mechanical circulatory support devices market growth over the forecast period.

Market Restraints - Impact & Negative CAGR Contribution (2026–2034)

Rank Market Restraints Expected Impact on Market Growth Estimated Reduction in Market Size (USD Billion)
(2026-2034)
Impact: 2026-2028 Impact: 2029-2031 Impact: 2032-2034
1 Risk of Device-Related Complications to Limit Market Growth High 0.82 High High High
2 High device/therapy cost and reimbursement or hospital-budget constraints Medium-High 0.57 High High Medium
3 Limited specialist centers and trained multidisciplinary MCS workforce Medium 0.42 Medium Medium Medium
4 Others (regulatory delays, supply-chain constraints, patient eligibility limits and competing therapies) Low 0.24 Low Low Low
Total Market Reduction 2.05  

Source: Fortune Business Insights

Download Free sample For In-Depth Market Restraints & Risk Analysis

MARKET OPPORTUNITIES

Growing Adoption of MCS in Emerging Markets to Create Lucrative Growth Opportunities

Emerging markets across China, India, Southeast Asia, Latin America, and the Gulf Cooperation Council (GCC) countries offer strong growth potential for the adoption of mechanical circulatory support devices. Adoption in these regions is generally lower than in North America and Europe, but the number of advanced cardiac centers and specialists is increasing.

Also, local manufacturing could improve device accessibility by reducing dependence on imports by reducing dependence on expensive imported products. Furthermore, adoption is expected to increase particularly in urban hospitals and specialized cardiac centers. Additionally, distributor partnerships, improved reimbursement mechanisms, local regulatory approvals, and greater affordability could support wider adoption.

MARKET CHALLENGES

Limited Availability of Specialized MCS Centers and Skilled Professionals to Challenge the Market Growth

In several countries, particularly emerging economies, the availability of multidisciplinary MCS teams remains limited, involving cardiac surgeons, heart-failure specialists, interventional cardiologists, intensivists, perfusionists, nurses, and other trained staff. This restricts MCS adoption, particularly outside major tertiary and cardiac centers.

  • For instance, according to the data published by the National Center for Biotechnology Information (NCBI) in August 2026, there is only 1 local cardiac surgeon for 12.0 million people across Asia Pacific.

Moreover, specialized MCS centers are often concentrated in major metropolitan areas, restricting MCS adoption in rural areas and potentially limiting market growth.

Segmentation Analysis

By Product Type

Growing Adoption in Cardiogenic Shock and High-Risk PCI Boosted Intracorporeal Catheter-Based Heart Pumps Segment Dominance

Based on product type, the market is segmented into intracorporeal catheter-based heart pumps, implantable ventricular assist devices, extracorporeal & paracorporeal circulatory support devices, intra-aortic balloon pump systems, total artificial hearts, and others. The intracorporeal catheter-based heart pumps segment is further sub-segmented into left-heart support pumps, right-heart support pumps, and others. The implantable ventricular assist devices segment is sub-classified into LVADs and RVADs & BiVADs. The extracorporeal & paracorporeal circulatory support devices segment is subdivided into left-heart support systems, right-heart support systems, and biventricular support systems. The intra-aortic balloon pump systems segment is sub-segmented into IABP consoles and intra-aortic balloon catheters.

The intracorporeal catheter-based heart pumps segment accounted for the largest global mechanical circulatory support devices market share in 2025. The segment’s growth is mainly driven by their growing utilization in cardiogenic shock and high-risk PCI procedures, where rapid short-term circulatory support is required. Moreover, these pumps are generally used for individual treatment episodes. This is expected to create a repetitive demand as procedure volumes increase.

The implantable ventricular assist devices segment is projected to grow at a 9.1% CAGR during the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Patient Group

Adults Segment Led Market Due to High Burden of Cardiac Conditions

By patient group, the market is segmented into adults and pediatric.

The adults segment accounted for the largest market share in 2025. The segment’s growth is attributed to a higher prevalence of advanced heart failure, cardiogenic shock, complex PCI, and post-cardiotomy complications among adult patients. Additionally, the growing geriatric population is anticipated to drive the segment’s growth in the coming years.

  • For instance, in October 2025, the World Health Organization (WHO) stated that India's elderly population aged 60 and above is projected to reach 426.0 million by 2050.

The pediatric segment is anticipated to grow at a CAGR of 12.8% over the forecast period.

By Application

Cardiogenic Shock & Acute Cardiac Failure Segment Led Market Due to Increasing Utilization of Temporary MCS

By application, the market is classified into chronic advanced & end-stage heart failure, cardiogenic shock & acute cardiac failure, high-risk PCI & procedural hemodynamic support, post-cardiotomy circulatory failure, and others.

The cardiogenic shock & acute cardiac failure segment accounted for the largest market share in 2025. The segment’s dominance is mainly due to the increasing prevalence of cardiogenic shock & acute cardiac failure and increasing use of temporary MCS devices to stabilize critically ill patients quickly. Furthermore, the segment is set to acquire a 34.6% share in 2026.

  • For instance, according to ABIOMED, more than 330,000 patients worldwide had reportedly received Impella support as of August 2024.

The chronic advanced & end-stage heart failure segment is expected to grow at a CAGR of 7.6% during the forecast period.

By End-user

Availability of Advanced Cardiac Care Infrastructure Supported Hospitals & ASCs Segment Dominance

On the basis of end-user, the market is segmented into hospitals & ASCs, specialty clinics, and others.

In 2025, the hospitals & ASCs segment dominated the market. Durable VAD implantation, post-cardiotomy support, cardiogenic shock treatment, and total artificial heart (TAH) procedures require advanced medical infrastructure, which hospitals and ASCs offer. This is expected to drive the segment’s growth during the forecast period. Furthermore, the segment is set to hold a 94.0% market share in 2026.

The specialty clinics segment is projected to grow at a CAGR of 12.2% during the forecast period.

Mechanical Circulatory Support Devices Market Regional Outlook

Based on geography, the market is classified into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

North America Mechanical Circulatory Support Devices Market Size, 2025 (USD Billion)

To get more information on the regional analysis of this market, Download Free sample

North America accounted for the largest share in 2024, valued at USD 1.71 billion, and maintained its leading position in 2025, with USD 1.95 billion. The region’s dominance is supported by strong adoption of temporary heart pumps in the U.S., well-established VAD programs, advanced transplant centers, and favorable reimbursement systems. For instance, as of September 2026, Transplants.org, Inc. stated that there are approximately 150 active heart transplant programs in the U.S.

U.S. Mechanical Circulatory Support Devices Market

In 2026, the U.S. is anticipated to reach USD 2.05 billion, accounting for approximately 51.1% of global sales.

Europe

Europe is projected to record a CAGR of 9.2% during the forecast period, the second-highest globally. The market is expected to reach USD 0.82 billion in 2026. The region’s growth is attributed to the presence of major players and availability of key professionals in the U.K., Germany, France, and Italy.

U.K. Mechanical Circulatory Support Devices Market

The U.K. market is projected to reach USD 0.14 billion in 2026, representing approximately 3.6% of global sales.

Germany Mechanical Circulatory Support Devices Market

The market in Germany is expected to reach USD 0.18 billion in 2026, accounting for approximately 4.5% of global revenues.

Asia Pacific

In 2026, the market in Asia Pacific is projected to reach approximately USD 0.80 billion, making it the third-largest market. The region’s growth is attributable to a large patient pool in the region and growing physician preference for MCS devices due to key advancements in such devices.

Japan Mechanical Circulatory Support Devices Market

The market in Japan is projected to reach approximately USD 0.20 billion in revenue in 2026, representing nearly 5.0% of global sales.

China Mechanical Circulatory Support Devices Market

In 2026, the market in China is anticipated to reach USD 0.27 billion, accounting for approximately 6.7% of global sales.

India Mechanical Circulatory Support Devices Market

In 2026, the market in India is anticipated to reach USD 0.09 billion, accounting for approximately 2.3% of global sales.

Latin America and Middle East & Africa

Latin America and the Middle East & Africa are anticipated to witness moderate growth during the forecast period. The market in Latin America is estimated to reach approximately USD 0.13 billion in 2026. Market growth is due to growing awareness of mechanical circulatory support devices in the emerging countries of the region. The Middle East & Africa market is mainly driven by key players entering the market to capture untapped opportunities in low-income areas.

GCC Mechanical Circulatory Support Devices Market

In 2026, the GCC market is estimated to reach approximately USD 0.06 billion, representing around 1.5% of global revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

Established Global Presence and Product Portfolios Support Competitive Position of Leading Companies

In 2025, Abbott, ABIOMED, Getinge, Teleflex Incorporated, and Berlin Heart were identified among the leading market participants. The significant share of these companies is attributed to their strong global footprint and diversified product portfolios. Moreover, other prominent players are focusing on strategic growth initiatives such as mergers and acquisitions, strategic collaborations, and partnerships, and increasing investments to strengthen their competitive positions during the forecast period.

LIST OF KEY MECHANICAL CIRCULATORY SUPPORT DEVICE COMPANIES PROFILED

  • Abbott (U.S.)
  • ABIOMED (U.S.)
  • Berlin Heart (Germany)
  • Getinge (Sweden)
  • Teleflex Incorporated (U.S.)
  • Shenzhen Core Medical Technology Co., Ltd (China)
  • Shenzhen Zhonghong Technology Co., LTD (China)
  • magAssist Co., Ltd (China)
  • LivaNova PLC (U.K.)
  • CARMAT (France)

KEY INDUSTRY DEVELOPMENTS

  • May 2026: ABIOMED reported results from the IMPACT pilot study, which evaluated the investigational use of Impella 5.5 in selected high-risk cardiac surgery patients.
  • April 2026: BrioHealth Solutions received FDA conditional approval for the Brio4Kids pediatric study, allowing the company to expand the development of BrioVAD for pediatric patients.
  • August 2025: BrioHealth Solutions received FDA approval to begin the pivotal phase of the INNOVATE clinical trial evaluating BrioVAD in patients with advanced heart failure.
  • February 2025: Abbott received FDA approval for the CentriMag circulatory support system, covering changes to its hardware and software.
  • April 2024: magAssist Co., Ltd received NMPA approval in China for its MoyoAssist extracorporeal VAD and began commercializing the device.
  • August 2023: magAssist Co., Ltd’s NyokAssist percutaneous VAD received FDA Breakthrough Device designation, supporting its further development in the U.S.

REPORT COVERAGE

The report offers an in-depth assessment of the global mechanical circulatory support devices market, covering its key segments and major growth drivers, restraints, opportunities, challenges, and market trends. It also evaluates technological advancements, key industry developments, product approvals, heart failure prevalence/incidence, the competitive landscape, company market share analysis, and profiles of leading market participants.

Request for Customization   to gain extensive market insights.


Report Scope and Segmentation

ATTRIBUTE DETAILS
Study Period 2021-2034
Base Year 2025
Estimated Year  2026
Forecast Period 2026-2034
Historical Period 2021-2024
Growth Rate CAGR of 10.0% from 2026 to 2034
Unit Value (USD Billion)
Segmentation By Product Type, Patient Group, Application, End-user, and Region
By Product Type
  • Intracorporeal Catheter-Based Heart Pumps
    • Left-Heart Support Pumps
    • Right-Heart Support Pumps
    • Others
  • Implantable Ventricular Assist Devices
    • LVADs
    • RVADs & BiVADs
  • Extracorporeal & Paracorporeal Circulatory Support Devices
    • Left-Heart Support Systems
    • Right-Heart Support Systems
    • Biventricular Support Systems
  • Intra-Aortic Balloon Pump Systems
    • IABP Consoles
    • Intra-Aortic Balloon Catheters
  • Total Artificial Hearts
  • Others
By Patient Group
  • Adults
  • Pediatric
By Application
  • Chronic Advanced & End-Stage Heart Failure
  • Cardiogenic Shock & Acute Cardiac Failure
  • High-Risk PCI & Procedural Hemodynamic Support
  • Post-Cardiotomy Circulatory Failure
  • Others
By End-user
  • Hospitals & ASCs
  • Specialty Clinics
  • Others
By Region
  • North America (By Product Type, Patient Group, Application, End-user, and Country)
    • U.S. (Application)
    • Canada (Application)
  • Europe (By Product Type, Patient Group, Application, End-user, and Country/Sub-region)
    • Germany (Application)
    • U.K. (Application)
    • France (Application)
    • Spain (Application)
    • Italy (Application)
    • Scandinavia (Application)
    • Rest of Europe (Application)
  • Asia Pacific (By Product Type, Patient Group, Application, End-user, and Country/Sub-region)
    • China (Application)
    • Japan (Application)
    • India (Application)
    • Australia (Application)
    • Southeast Asia (Application)
    • Rest of Asia Pacific (Application)
  • Latin America (By Product Type, Patient Group, Application, End-user, and Country/Sub-region)
    • Brazil (Application)
    • Mexico (Application)
    • Rest of Latin America (Application)
  • Middle East & Africa (By Product Type, Patient Group, Application, End-user, and Country/Sub-region)
    • GCC (Application)
    • South Africa (Application)
    • Rest of Middle East & Africa (Application)

Research Methodology

1. Bottom Up Approaches

Approach 1: Revenues and Market Share of Major MCS Players

  • Collection of MCS-attributable revenues from annual reports, SEC filings, investor presentations, earnings releases, and company disclosures of key manufacturers such as Johnson & Johnson/Abiomed, Abbott, Getinge, Teleflex, Berlin Heart, and other regional players.
  • Estimation of company market shares based on product revenues, geographic presence, device portfolio, installed base, implant/procedure volumes, and commercialization status.
  • Triangulation of company-level MCS revenues with regional device utilization and country-level demand indicators to derive the global market estimate.

Approach 2: Device Volume × Average Selling Price Analysis

  • Collection of annual unit/implant volumes for catheter-based heart pumps, durable VADs, extracorporeal/paracorporeal MCS systems, IABP systems, and total artificial hearts.
  • Estimation of manufacturer-level ASPs by product type, country, and region, including applicable recurring revenue from catheters, cannulas, pump sets, controllers, batteries, and other device-specific consumables.
  • Multiplication of device volumes by ASPs and summation of country/regional estimates to arrive at the global market size.
  • Cross-checking calculated revenues with reported manufacturer MCS revenues.

Approach 3: Patient, Procedure & Treatment-Capacity Model

  • Assessment of diagnosed and treatment-eligible patient pools across advanced/end-stage heart failure, cardiogenic shock, acute cardiac failure, high-risk PCI, and post-cardiotomy circulatory failure.
  • Mapping of eligible patients to annual MCS utilization, including durable VAD implantation, temporary heart-pump use, IABP procedures, and other qualifying MCS interventions.
  • Analysis of heart-transplant waiting lists, transplant volumes, advanced heart-failure centers, cath labs, cardiac surgery centers, and trained MCS teams.
  • MCS-treated patient/procedure volumes were multiplied by relevant device utilization rates and manufacturer ASPs to estimate country and regional market values.

2. Top-Down Approaches

Approach 4: Analysis of Parent Cardiovascular / Advanced Heart-Failure Device Markets

  • Analysis of the broader cardiovascular medical devices and advanced heart-failure treatment ecosystem, followed by estimation of the proportion attributable specifically to mechanical circulatory support devices.
  • Assessment of the contribution from catheter-based heart pumps, durable VADs, extracorporeal/paracorporeal support systems, IABPs, and total artificial hearts.
  • Validation using heart-failure burden, cardiogenic-shock incidence, high-risk PCI volumes, transplant activity, hospital infrastructure, regulatory approvals, and MCS adoption trends.
  • Reconciliation with bottom-up manufacturer revenues and device-volume estimates to establish the final market size.

3. List of Key Sources

  • Company Sources
    • Annual Reports
    • SEC Filings / 10-K / 20-F
    • Investor Presentations
    • Earnings Releases & Transcripts
    • Company Websites
    • Product Catalogs
    • Regulatory Announcements
    • Clinical Trial Updates
  • Regulatory & Government Sources
    • S. FDA
    • European Commission / EU MDR
    • PMDA
    • NMPA
    • CDSCO
    • TGA
  • Clinical Associations, Societies & Registries
    • STS INTERMACS
    • ISHLT
    • AHA
    • ACC
    • ESC
    • EACTS
    • ELSO, where relevant for validation
  • Global & Public Healthcare Sources
    • WHO
    • OECD
    • World Bank
    • Eurostat
    • National health statistics agencies
    • Cardiovascular diseases and public transplant databases
    • Peer-reviewed MCS, VAD, heart-failure, cardiogenic-shock, and high-risk PCI publications

4. Primary Interviews

Supply Side Interviews: 60%

  • Key Respondents:
    • MCS manufacturers, distributors, sales executives, product managers, marketing managers, regional business heads, procurement specialists, and device suppliers.
    • Discussions focused on market size, device volumes, ASPs, product mix, competitive positioning, geographic penetration, distribution structure, commercialization, and growth trends.

Demand Side Interviews: 40%

  • Key Respondents:
    • Cardiologists, interventional cardiologists, cardiac surgeons, heart-failure specialists, transplant physicians, perfusionists, cath-lab teams, hospital procurement managers, and MCS program coordinators.
    • Discussions focused on MCS utilization, patient selection, procedure volumes, preferred technologies, reimbursement, hospital adoption, procurement practices, device pricing, and country-level treatment patterns.


Frequently Asked Questions

Fortune Business Insights says that the global market value stood at USD 3.59 billion in 2025 and is projected to reach USD 8.58 billion by 2034.

In 2025, the market value in North America stood at USD 1.95 billion.

The market is expected to exhibit a CAGR of 10.0% during the forecast period.

By product type, the intracorporeal catheter-based heart pumps segment led the market.

Growing use of temporary MCS in cardiogenic shock and high-risk PCI fuels market growth.

Abbott, ABIOMED, Getinge, Teleflex Incorporated, and Berlin Heart are among the top players in the market.

North America dominated the market in 2025.

Seeking Comprehensive Intelligence on Different Markets?Get in Touch with Our Experts Speak to an Expert
  • 2021-2034
  • 2025
  • 2021-2024
  • 250
Download Free Sample

    man icon
    Mail icon
    Mail icon
Jump to Content

Get 30-60 hrs Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Healthcare Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann